10x Genomics Reports Q3 2026 Results with Raised Full-Year Revenue Guidance
10x Genomics (TXG) reported third-quarter revenue of $150.7 million, representing a 1% year-over-year increase driven primarily by strength in consumables. Despite a decline in instrument revenue as customers moderated purchases ahead of new platform launches, the company improved its operating loss to $16.1 million from $32.2 million in the prior year period. Gross margins saw a significant expansion to 75%, up from 67% in Q3 2025. The company raised its full-year revenue guidance to a range of $625 million to $635 million, citing stronger third-quarter performance. Looking ahead, management is focusing on the rollout of the Atera platform, projecting 50 instrument shipments by year-end. However, leadership cautioned that gross margins may face sequential pressure as the product mix shifts toward newly launched hardware and manufacturing scales up.
Tickers: $AAPL $AMZN $GOOG $META $MSFT $NVDA $TSLA $TXG
Topics: Consumables Revenue Gross Margin Improvement Guidance Raise Revenue Growth